Wu Chao, Gudivada Ranga C, Aronow Bruce J, Jegga Anil G
BMC Syst Biol. 2013;7 Suppl 5(Suppl 5):S6. doi: 10.1186/1752-0509-7-S5-S6. Epub 2013 Dec 9.
Given the costly and time consuming process and high attrition rates in drug discovery and development, drug repositioning or drug repurposing is considered as a viable strategy both to replenish the drying out drug pipelines and to surmount the innovation gap. Although there is a growing recognition that mechanistic relationships from molecular to systems level should be integrated into drug discovery paradigms, relatively few studies have integrated information about heterogeneous networks into computational drug-repositioning candidate discovery platforms.
Using known disease-gene and drug-target relationships from the KEGG database, we built a weighted disease and drug heterogeneous network. The nodes represent drugs or diseases while the edges represent shared gene, biological process, pathway, phenotype or a combination of these features. We clustered this weighted network to identify modules and then assembled all possible drug-disease pairs (putative drug repositioning candidates) from these modules. We validated our predictions by testing their robustness and evaluated them by their overlap with drug indications that were either reported in published literature or investigated in clinical trials.
Previous computational approaches for drug repositioning focused either on drug-drug and disease-disease similarity approaches whereas we have taken a more holistic approach by considering drug-disease relationships also. Further, we considered not only gene but also other features to build the disease drug networks. Despite the relative simplicity of our approach, based on the robustness analyses and the overlap of some of our predictions with drug indications that are under investigation, we believe our approach could complement the current computational approaches for drug repositioning candidate discovery.
鉴于药物发现与开发过程成本高昂、耗时且损耗率高,药物重新定位或药物用途拓展被视为一种可行策略,既能补充枯竭的药物研发线,又能跨越创新差距。尽管人们越来越认识到应将从分子到系统层面的机制关系整合到药物发现范式中,但相对较少的研究将异质网络信息整合到计算药物重新定位候选发现平台中。
利用KEGG数据库中已知的疾病 - 基因和药物 - 靶点关系,我们构建了一个加权疾病和药物异质网络。节点代表药物或疾病,边代表共享基因、生物学过程、通路、表型或这些特征的组合。我们对这个加权网络进行聚类以识别模块,然后从这些模块中组装所有可能的药物 - 疾病对(推定的药物重新定位候选物)。我们通过测试预测的稳健性来验证预测,并通过它们与已发表文献中报道或临床试验中研究的药物适应症的重叠来评估它们。
先前用于药物重新定位的计算方法要么侧重于药物 - 药物和疾病 - 疾病相似性方法,而我们采用了更全面的方法,也考虑了药物 - 疾病关系。此外,我们不仅考虑基因,还考虑其他特征来构建疾病 - 药物网络。尽管我们的方法相对简单,但基于稳健性分析以及我们的一些预测与正在研究的药物适应症的重叠,我们相信我们的方法可以补充当前用于药物重新定位候选发现的计算方法。